Your session is about to expire
← Back to Search
Difelikefalin for Itching in Chronic Kidney Disease
Study Summary
This trial is testing a drug to see if it can help people with kidney disease who have moderate to severe itchiness. The trial has two parts, the first is 12 weeks to see if the drug works and the second is up to 52 weeks to see if the drug has any long term effects.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowExclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Travel, including flights, are covered
Your expenses for travel tickets for this trial will be reimbursed.
Other reimbursement is provided
Other forms of reimbursement are provided for this trial.
Who is running the clinical trial?
Media Library
- I haven't started or changed itch treatment in the last 14 days.I am scheduled for a kidney treatment like dialysis or transplant.I am currently undergoing dialysis.I have had itchy skin almost every day for the last 6 months.My kidney disease is in stage 4 or 5.My itchiness didn't improve with creams or lotions.
- Group 1: Difelikefalin 1 mg Oral Tablet
- Group 2: Placebo Oral Tablet
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 4 Weeks to process to see if you qualify in this trial.
- Treatment: You will receive the treatment for 12 Weeks
- Follow Ups: You may be asked to continue sharing information regarding the trial for 1 Weeks after you stop receiving the treatment.
Frequently Asked Questions
Is this experiment actively looking for individuals to test its treatments on?
"Yes, this research is still looking for participants. According to the website clinicaltrials.gov, the trial was originally posted on August 26th, 2022 and updated September 27th, 2022."
Are patients under the age of 20 eligible for this clinical trial?
"As per the requirements for this study, volunteers must be between 18-85 years old."
Has Difelikefalin 1 mg Oral Tablet earned FDA approval?
"Difelikefalin 1 mg Oral Tablet has received a 3 for safety. This is based on the fact that it is currently in Phase 3 trials, indicating that there is some efficacy data as well as multiple rounds of safety data."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Most responsive sites:
- Cara Therapeutics Study Site: < 24 hours
Average response time
- < 2 Days
Typically responds via
Share this study with friends
Copy Link
Messenger